The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia

Yutaka Imai, Hiromichi Suzuki, Takao Saito, Ichiro Tsuji, Keishi Abe, Takao Saruta

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)

Abstract

The effect of pravastatin on renal function in hypertensive patients with mild renal dysfunction and hyperlipidemia was examined. A total of 57 subjects given dihydropyridine calcium blockers were randomly assigned to placebo (n = 25) and pravastatin groups (n = 32). The period of study was 6 months. In the placebo group, lipid metabolism did not change throughout the study period, but the serum creatinine concentration (Scr) increased from a baseline of 1.6±0.07 mg/dl to 2.1±0.2 mg/dl in the 6th month of study and blood urea nitrogen (BUN) increased from 26.2±1.1 mg/dl to 32.4±30.1 mg/dl. In the pravastatin group, the serum total cholesterol decreased from a baseline of 251.4±7.3 mg/dl to 218.2±6.5 mg/dl in the 6th month of study, while Scr (1.3±0.07 mg/dl vs 1.3±0.09 mg/dl) and BNU (20.5±1.2 mg/dl vs 21.0±1.4 mg/dl) did not change. The change in Scr in the placebo group was significantly different from that in the pravastatin group (F = 3.75, p = 0.05). The slope of the change in 1/Scr was 0.02 ± 0.07 dl·mg-1·month- 1 in placebo group and -0.01 ± 0.03 dl·mg-1·month-1 in pravastatin group (P<0.05). The results indicate that pravastatin attenuates the deterioration of renal function in patients with mild renal dysfunction, together with an improvement of lipid metabolism.

Original languageEnglish
Pages (from-to)1345-1355
Number of pages11
JournalClinical and Experimental Hypertension
Volume21
Issue number8
DOIs
Publication statusPublished - 1999 Nov

Keywords

  • Calcium entry blocker
  • Hyperlipidemia
  • Hypertension
  • Pravastatin
  • Renal dysfunction

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology

Fingerprint Dive into the research topics of 'The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia'. Together they form a unique fingerprint.

Cite this